We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Rejects Boehringer Ingelheim’s Empagliflozin for Type 1 Diabetes
Advisory Committee Rejects Boehringer Ingelheim’s Empagliflozin for Type 1 Diabetes